Back

Helmet Use Among E-Bike, Pedal Bike, and E-Scooter Riders in Canberra: Retrospective Data Analysis of Head Injury Presentations (Phase 3)

Silburn, A.

2026-03-05 public and global health
10.64898/2026.03.04.26347649 medRxiv
Show abstract

BackgroundHelmet use is a proven safety measure that reduces the risk of head injury among cyclists and e-scooter riders. Despite legal requirements for pedal bikes and e-bikes in Australia, compliance varies, particularly among users of electric vehicles. The growing popularity of e-bikes and e-scooters in urban areas presents new public health challenges, yet observational data on helmet use, behavioural determinants, and the effectiveness of safety interventions remain limited. AimPhase 3 of the Helmet Use in Canberra study aims to characterise head injury presentations associated with cycling and e-scooter use and examine their association with helmet use and injury severity. MethodsDe-identified emergency department records from The Canberra Hospital will be retro-spectively analysed for presentations involving cycling or e-scooter-related head injuries during the study period. Extracted variables will include age, sex, vehicle type, documented helmet use, injury diagnosis, severity indicators, and date/time of presentation. Descriptive statistics will summarise injury patterns, while regression analyses will evaluate associations between helmet use and injury severity, controlling for demographic and contextual factors. Sensitivity analyses will address missing helmet data and subgroup differences by vehicle type, age, and gender. Expected ResultsIt is hypothesised that lower helmet use will correlate with higher rates and greater severity of head injury presentations. Findings will provide a population-level perspective on helmet effectiveness, inform local injury prevention strategies, and guide public safety interventions. Trial RegistrationAustralian and New Zealand Clinical Trials Registry (ANZCTR) [ACTRN12626000245392]

Matching journals

The top 4 journals account for 50% of the predicted probability mass.

1
BMJ Open
554 papers in training set
Top 0.3%
28.5%
2
PLOS ONE
4510 papers in training set
Top 11%
15.2%
3
Journal of Public Health
23 papers in training set
Top 0.1%
4.1%
4
Trials
25 papers in training set
Top 0.4%
3.7%
50% of probability mass above
5
Public Health in Practice
11 papers in training set
Top 0.1%
1.9%
6
BMC Medicine
163 papers in training set
Top 3%
1.9%
7
BMJ Global Health
98 papers in training set
Top 2%
1.7%
8
Emergency Medicine Journal
20 papers in training set
Top 0.3%
1.7%
9
Systematic Reviews
11 papers in training set
Top 0.2%
1.7%
10
International Journal of Public Health
17 papers in training set
Top 0.1%
1.7%
11
International Journal of Environmental Research and Public Health
124 papers in training set
Top 4%
1.5%
12
PLOS Medicine
98 papers in training set
Top 3%
1.5%
13
JAMA Network Open
127 papers in training set
Top 2%
1.5%
14
BMC Public Health
147 papers in training set
Top 4%
1.5%
15
Archives of Disease in Childhood
15 papers in training set
Top 0.3%
1.4%
16
Journal of Epidemiology and Community Health
32 papers in training set
Top 0.4%
1.3%
17
Eurosurveillance
80 papers in training set
Top 1.0%
1.3%
18
Frontiers in Neurology
91 papers in training set
Top 4%
1.3%
19
The Lancet Infectious Diseases
71 papers in training set
Top 2%
0.9%
20
PLOS Global Public Health
293 papers in training set
Top 5%
0.9%
21
Annals of Epidemiology
19 papers in training set
Top 0.5%
0.8%
22
Public Health
34 papers in training set
Top 2%
0.8%
23
European Journal of Public Health
20 papers in training set
Top 1%
0.8%
24
Medicine & Science in Sports & Exercise
15 papers in training set
Top 0.4%
0.8%
25
Medicine
30 papers in training set
Top 2%
0.8%
26
Cureus
67 papers in training set
Top 5%
0.8%
27
The American Journal of Tropical Medicine and Hygiene
60 papers in training set
Top 4%
0.7%
28
BMJ Paediatrics Open
21 papers in training set
Top 0.9%
0.7%
29
Preventive Medicine
11 papers in training set
Top 0.4%
0.7%
30
EClinicalMedicine
21 papers in training set
Top 1%
0.7%